Targeting a Regulator of Inflammation to Treat Alzheimer's Disease

The Bio Report

David Bearss Ph.D., president and CEO of Halia Therapeutics, Inc., discusses with Daniel Levine the NLRP3 inflammasome, the role it plays in Alzheimer’s disease and other neurologic conditions, and the case for the company's therapeutic approach.

https://thebioreport.podbean.com/e/targeting-a-regulator-of-inflammation-to-treat-alzheimer-s-disease/

March 22, 2023